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Imidazo[2,1-b][1,3,4] thiadiazole derivatives are significant for their various pharmacolog-
ical properties. This paper reports the synthesis and structure of one of them, 2-cyclohexyl-
6-(2-oxo-2H-chromen-3-yl)imidazo[2,1-b][1,3,4]thiadiazole-5-carbaldehyde. The com-
pound crystallizes in the monoclinic space group P21/c with a = 17.316(3)Å,
b = 6.5420(9)Å, c = 17.056(3)Å, β = 112.909(2)◦, V = 1779.7(4)Å3, z = 4. The,
Imidazo[2,1-b][1,3,4] thiadiazole and the coumarin ring systems are each planar but in-
clined at an angle of 48.14(2)◦ towards each other. The crystal structure is stabilized by
C–H . . . O interactions.
KEY WORDS: Imidazo[2,1-b][1,3,4] thiadiazole derivatives; Coumarin; Vilsmeier-Haack reaction; crystal
structure analysis.
Introduction
Imidazo[2,1-b][1,3,4] thiadiazole (IT) deriva
tives with pharmacophoric substituents have
promising biological and pharmacological activi-
ties. The title compound is one of such derivatives,
with a coumarin molecule linked to the IT ring
system.
The IT ring is bioisosteric with the
Imidazo[2,1-b]thiazole ring present in the well
known anthelmintic drug ‘Tetramisole.’1 In this
regard, a large number of IT derivatives have been
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reported to possess diverse pharmacological prop-
erties viz., antibacterial,2 analgesic3 and an-
thelmintic4 activities. Coumarin derivatives are
also found in varieties of natural products5 and
many of them display pharmacological proper-
ties.6–9 Apart from this, coumarins are of consid-
erable general importance and are prominent in
natural products chemistry. They have been found
to possess a wide variety of uses in the perfume
industry, as flavor enhancers, sunscreens and laser
dyes. Encouraged by thesewide variety of appli-
cations, we thought it might be interesting to link
coumarin molecule with the biologically active IT
moiety expecting a molecule with enhanced bio-
logical activity. These molecules were prepared
as precursors during the synthesis of potential an-
tidiabetic thiazolidine-2,4-dione derivatives of IT.
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The title compound was synthesized using
Vilsmeier-Haack reagent which was made to react
with the prepared 3-(2-cyclohexylimidazo[2,1-b]
[1,3,4]thiadiazol-6-yl)-2H-chromen-2-one. This
was followed by measurement of analytical data
relating to the compound.
The compound was then subjected to spec-
troscopic analysis using IR and1H NMR tech-
niques to confirm the presence of the supposed
ring system, formylation at the appropriate posi-
tion and the signals for the existence of aldehydic
and other protons.
A single crystal X-ray diffraction analysis
was carried out on the compound to investigate
the geometry of the coumarin moiety and also
possible contributions like intramolecular inter-
actions towards the stabilization of the molecule.
The analysis revealed certain interesting features
like the individual planarity of the two ring sys-
tems despite the presence of non-planarity in their
combined structure. Also, the cyclohexyl ring is
found to be in chair conformation. No interesting
intramolecular hydrogen bonding is observed, al-
though there is an infinite zigzag pattern of link-
age between molecules, brought about by several
directionally specific C–H . . . O interactions.
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Experimental
Synthesis and characterization
The title compound was prepared in two
stages as shown in Scheme 1. The reaction
of 2-amino-5-cyclohexyl-1,3,4-thiadiazole10 (1)
and 3-bromoacetyl coumarin11(2) in boiling
ethanol afforded 3-(2-cyclohexylimidazo[2,1-b]-
[1,3,4]thiadiazol-6-yl)-2H-chromen-2-one (3) as
hydrobromide salt, which was neutralized by
sodium carbonate solution to get the free base. It
was subjected to Vilsmeir Haack reaction to yield
2-cyclohexyl-6- (2-oxo-2H-chromen-3-yl) imi-
dazo [2,1-b][1,3,4] thiadiazole-5-carbaldehyde
(4). The structures of the synthesized compounds
were established by analytical and spectral data.
3-(2-cyclohexylimidazo[2,1-b]- [1,3,4]thia-
diazol-6-yl)-2H-chromen-2-one (3). Equimolar
quantities of 2-amino-5-cyclohexyl-1,3,4-
thiadiazole (1.83 g, 0.01 mol) and 3-bromoacetyl
coumarin (2.67 g, 0.01 mol) were refluxed in
absolute ethanol for 8 h. The resultant solid
(hydrobromide) was separated by filtration. The
free base was obtained by neutralization with
sodium carbonate solution. It was washed with
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water and recrystallised from alcohol as an
yellow amorphous solid. (Compound 3: Yield
58%; mp 182–184◦C).
2-cyclohexyl-6- (2-oxo-2H-chromen-3-yl)
imidazo [2,1-b][1,3,4] thiadiazole-5-carbal-
dehyde (4). Vilsmeier- Haack reagent was
obtained by adding POCl3 (3 ml) in DMF (20 ml)
at 0◦C, with stirring. Compound 3 (3.51 g,
0.01 mol) was added to the reagent and stirred at
0◦C for 30 min. The mixture was further stirred
at room temperature for 2 h and at 60◦C for
additional 2 h. The reaction mixture was then
poured into sodium carbonate solution and stirred
at 90◦C for 2 h. After cooling, the mixture was
diluted with water, extracted with chloroform
and the chloroform extracts were washed with
water, dried over anhydrous sodium sulphate. The
solvent was removed under reduced pressure to
yield the residual solid, which was recrystallised
from chloroform and hexane mixture (90:10) to
get pale yellow crystalline solid. (Compound 4:
Yield 66%; mp. 176–178◦C).
Physical measurements
Melting points were determined in open
capillaries and are uncorrected. IR spec-
tra were recorded on Nicolet FT-IR 410
spectrophotometer.1H NMR spectra were
recorded on Varian RX-300 MHz spectrometer
using TMS as internal standard.
The Infrared spectra of imidazo[2,1-
b][1,3,4]thiadiazole derivatives does not contain
absorption band due to υC=O (ketone carbonyl
of bromoacetyl coumarin),υNH2 and presence of
lactone υC=O confirming the formation of imidazo
[2,1-b]-[1,3,4]thiadiazoles. The1H NMR spectra
(CDCl3) showed appropriate signals due to differ-
ent protons present in the molecule. The formy-
lation products showed a band due to υC=O in its
IR spectra and a singlet due to aldehyde proton
in the NMR spectrum. The absence of singlet due
to C5-H was considered as the confirmation of
formylation at C5.
Compound 3: IR (KBr) cm−1 1734 (υC=O,
lactone), 1600 (υC=N);1H NMR(CDCl3) δ,
1.26–3.03 (m, 11H, cyclohexyl), 7.32–7.60 (m,
4H, coumarinyl), 8.57 (s, 1H, C4H, coumarin),
8.63 (s, 1H, C5H imidazole); Anal.Calcd for, C19
H17 N3 O2 S; C, 64.94; H, 4.88; N, 11.96; Found;
C, 64.85; H, 4.82, N, 11.90.
Compound 4: IR (KBr) cm−1; 2858 (υC−H
aldehyde), 1736(υC=O, lactone), 1676(υC=O,
aldehyde) 1601 (υC=N);1H NMR (CDCl3) δ 1.30–
3.52 (m, 11H, cyclohexyl), 6.92–7.64 (m, 4H,
coumarinyl), 8.33 (s, 1H, C4-H coumarin), 10.21
(s, 1H, aldehyde); Anal.Calcd for, C20 H17 N3 O3
S; C, 63.31; H, 4.52; N, 11.07; found, C, 63.27;
H, 4.38; N, 11.10.
Crystal structure determination of (4)
The X-ray diffraction data were collected on
a Bruker Smart CCD Area Detector System using
Table 1. Crystal Data and Structure Refinement
Empirical formula C20 H17 N3 O3 S
Formula weight 379.43
Temperature (K) 293(2)
Wavelength (A) 0.71073
Crystal system Monoclinic
Space group P21/c
Cell dimensions
a (Å) 17.316(3)
b (Å) 6.5420(9)
c (Å) 17.056(3)
ß (◦) 112.909(2)
Volume (Å3) 1779.7(4)
Z 4
Density(Calculated)(Mg/m3) 1.416
Absorption coefficient (mm−1) 0.209
F(000) 792
Crystal size 0.1 mm × 0.2 mm × 0.25 mm
 range for data collection 2.40 to 27.99◦
Index ranges −22 < = h < = 22
−8 < = k < = 8
−22 < = l < = 22
Reflections collected 14876
Independent reflections 4234 [R(int) = 0.0306]
Refinement method Full–matrix least–squares on F2
Data/restraints/parameters 4234/0/268
Goodness-of-fit on F2 1.128
Final R indices [I > 2sigma(I)] R1 = 0.0601, wR2 = 0.1222
R indices (all data) R1 = 0.0862, wR2 =0.1316
Largest diff. peak and hole
(e. A−3)
0.313 and −0.218
CCDC deposit no. 271066.
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Mo-Kα radiation (λ= 0.71073Å), to θmax of 28.00
in ω–	 scan mode. The data were processed using
SAINTPLUS12 and absorption corrections were
applied in SADABS13 A total of 14876 reflections
was collected, resulting in 4234 (Rint = 0.031); of
these, the number of ‘observed’ reflections (with
I > 2 σ (I)) was 3218. Corrections for Lorentz
and polarization effects were applied. The struc-
ture was solved by direct methods and difference
Fourier synthesis using SHELXS97.14 The posi-
Table 2. Selected Bond Lengths [Å] and Angles [◦]
S(1)–C(8) 1.721(2)
S(1)–C(2) 1.762(2)
N(3)–C(2) 1.295(2)
N(3)–N(4) 1.375(2)
O(14)–C(15) 1.378(3)
O(14)–C(12) 1.383(2)
N(4)–C(8) 1.349(3)
N(4)–C(5) 1.388(2)
O(13)–C(12) 1.197(2)
O(10)–C(9) 1.211(3)
C(6)–N(7) 1.376(3)
C(6)–C(5) 1.384(3)
C(21)–C(11) 1.338(3)
N(7)–C(8) 1.322(3)
C(8)–S(1)–C(2) 88.0(1)
C(2)–N(3)–N(4) 108.0(2)
C(15)–O(14)–C(12) 122.3(2)
C(8)–N(4)–N(3) 118.5(2)
C(8)–N(4)–C(5) 107.7(2)
N(3)–N(4)–C(5) 133.8(2)
N(7)–C(6)–C(5) 112.2(2)
N(7)–C(6)–C(11) 118.6(2)
C(5)–C(6)–C(11) 129.2(2)
C(21)–C(11)–C(6) 121.4(2)
C(12)–C(11)–C(6) 118.0(2)
N(3)–C(2)–C(22) 124.7(2)
N(3)–C(2)–S(1) 116.2(1)
C(22)–C(2)–S(1) 119.0(1)
O(13)–C(12)–O(14) 116.7(2)
O(13)–C(12)–C(11) 126.4(2)
O(14)–C(12)–C(11) 116.9(2)
O(14)–C(15)–C(16) 117.8(2)
O(14)–C(15)–C(20) 120.5(2)
C(6)–C(5)–N(4) 103.4(2)
N(4)–C(5)–C(9) 122.4(2)
C(8)–N(7)–C(6) 103.6(2)
O(10)–C(9)–C(5) 123.7(2)
N(7)–C(8)–N(4) 113.0(2)
N(7)–C(8)–S(1) 137.6(2)
N(4)–C(8)–S(1) 109.3(1)
tions of all non-hydrogen atoms were included
in the full-matrix least-square refinement using
SHELXL97.15 Anisotropic refinement using full-
matrix least-square procedures was carried out for
a few cycles until convergence was reached. The
hydrogen atoms were fixed geometrically; those
on the coumarin moiety and in the aldehyde group
were then refined freely, while the remainder were
set to ride on the parent carbon atoms. The fi-
nal R factors were wR2 = 0.132 and R1 = 0.086
for all 4234 reflections, and R1 = 0.060 for the
‘observed’ data; the maximum and the minimum
values of residual electron density were 0.3 and
–0.2 eÅ−3. Molecular diagrams were generated
using ORTEP.16 The details of crystal data and
refinement are given in Table 1.
Results and discussion
The selected bond distances and angles are
given in Table 2. Table 3 shows the selected tor-
sion angles. The ORTEP diagram of the molecule
is shown in Fig. 1.
The bond lengths and angles in 4 are within
normal ranges.17 The angle between the IT group
and the coumarin moieties is 48.14(2)◦, showing
deviation from planarity, as observed for other
coumarin derivatives.18,19 The two ring systems
are each planar.
Table 3. Selected Torsion Angles [◦]
N(7)–C(6)–C(11)–C(21) −46.3(3)
C(5)–C(6)–C(11)–C(21) 136.4(2)
N(7)–C(6)–C(11)–C(12) 126.5(2)
C(5)–C(6)–C(11)–C(12) −50.8(3)
C(27)–C(22)–C(2)–N(3) −114.1(2)
C(23)–C(22)–C(2)–S(1) −169.65(15)
C(6)–C(11)–C(12)–O(13) 1.1(3)
C(6)–C(11)–C(12)–O(14) −177.52(17)
C(11)–C(6)–C(5)–N(4) 176.67(18)
N(7)–C(6)–C(5)–C(9) 174.5(2)
C(11)–C(6)–C(5)–C(9) −8.1(4)
C(8)–N(4)–C(5)–C(9) −175.33(18)
N(3)–N(4)–C(5)–C(9) 6.0(3)
C(6)–C(5)–C(9)–O(10) −6.3(4)
N(4)–C(5)–C(9)–O(10) 168.16(19)
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Fig. 1. The molecular structure and atom labeling scheme of the title compound.
The coumarin skeleton geometry can be
compared with that of unsubstituted coumarin.
20 of coumarin-3-carboxylic acid21 and of
3-(bromoacetyl) coumarin.22 The double-bond
character of C11 –C21 is observed in all these
compounds. The C12–C11 and C21–C20 bonds,
adjacent to the double bond, are systematically
longer than 1.40 Å in these four molecules. The
angles C16–C15–O14 and C19–C20–C21 at the
junction of the two rings are, respectively, smaller
and greater than 120◦. The angles around C12
follow the same behavior in all the compounds.
Compared with unsubstituted coumarin,20
the decrease in the C12–C11–C21 bond angle by
2◦ and increase in C11–C21–C20 by the same
amount may be due to the IT group substituted at
C11.
Fig. 2. View of (i) C–H . . . O interaction (ii) Intermolecular
short contacts between cyclohexyl proton and coumarin ring.
The C12–O13 1.996 (3) Å, C12–C11 1.462
(3) Å and C11– C21 1.337 (3) Å distances show
conjugation of the C–O, C–C and C = C bonds.
Carbaldehyde group is inclined at an angle of
9.77(5)◦ to the IT group.
No interesting intramolecular hydrogen
bonding is seen in the molecule. However, in
this crystal structure, the molecule is linked
to its neighbors by several directionally spe-
cific C–H. . .O interactions [C21–H21 · · · O10,
C . . . O distance being 3.293(3) Å and C–
H . . . O angle being 168(2)◦, Fig. 2]. Other
significant intermolecular short contacts are be-
tween H24b of cyclohexane ring and the face of a
neighboring coumarin ring with C12 . . . H24b
and C15 . . . H24b distances being 2.881 and
2.891 Å respectively [Fig. 2].
Supplementary material CCDC 271066 contains the supplemen-
tary crystallographic data for this paper. These data can be ob-
tained free of charge at www.ccdc.com.ac.uk/conts/retrieving.html
or from the Cambridge Crystallographic Data Centre(CCDC), 12
Union Road, Cambridge CB2 1BZ. UK: fax: + 44(0)1223.336033:
e-mail: deposit@ccdc.com.ac.uk.
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